Business Context and Reporting Period
This Form 8-K Current Report was filed by Achieve Life Sciences, Inc. on August 20, 2024, regarding corporate governance changes effective August 21, 2024. The filing details the departure of the former Chief Executive Officer (CEO) and the appointment of new leadership for the CEO and Executive Chairman roles.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and severance terms.
- Former CEO Severance (John Bencich): 18 months of base salary, 18 months of healthcare premiums, 30 days of salary in lieu of notice, and accelerated vesting of time-based options equivalent to 18 months.
- New CEO Compensation (Richard Stewart): $615,000 annual base salary, up to 50% discretionary bonus, 157,500 performance-based RSUs, and options to purchase 67,500 shares.
- New Executive Chairman Compensation (Thomas B. King): $495,000 annual base salary, up to 50% discretionary bonus, options to purchase 195,000 shares, and 455,000 performance-based RSUs.
Material Changes Versus Prior Period
The primary material change is the complete turnover of the company's top executive leadership:
- Departure: John Bencich resigned as CEO, Principal Executive Officer, Principal Financial Officer, and Director. He will serve as an advisor until December 31, 2024.
- Appointment: Richard Stewart was appointed CEO, Principal Executive Officer, and Principal Financial Officer. He previously served as Executive Chairman.
- Board Transition: Thomas B. King was appointed Executive Chairman, replacing Mr. Stewart. Mr. King stepped down from his roles as chair and member of the Compensation Committee, member of the Audit Committee, and member of the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of market risks. The primary contingency noted is a "Change in Control" provision within Mr. Bencich's separation agreement, which would trigger additional severance payments (6 months salary, 6 months healthcare, and 24 months of average bonus) if such an event occurs within three months of his separation.
Board committee memberships were restructured effective August 21, 2024:
- Compensation Committee: Thomas Sellig appointed as Chair; members include Bridget Martell and Vaughn B. Himes.
- Nominating and Corporate Governance Committee: Bridget Martell appointed as Chair; members include Stuart Duty and Vaughn B. Himes.
- Audit Committee: Stuart Duty appointed as Chair; members include Bridget Martell and Thomas Sellig.
Investor Verification Checklist
- Verify the execution of the Separation Agreement with John Bencich to confirm the vesting of equity awards and severance payments.
- Review the upcoming Form 10-Q for the quarter ending September 30, 2024, for the full text of the Separation Agreement, Advisor Agreement, and King Employment Agreement.
- Monitor the company's cash position to assess the impact of the immediate severance obligations and new executive salaries.
- Confirm the timeline for the vesting of the new equity grants awarded to Richard Stewart and Thomas B. King.